Efficacy of sotalol in controlling reentrant supraventricular tachycardias.
Sotalol is unique among beta-blocking agents having significant Class III antiarrhythmic action. In a series of 22 patients with Wolff-Parkinson-White (WPW) syndrome and seven patients with atrioventricular nodal reentry tachycardia (AVNRT) resistant to multiple drugs, sotalol was studied by acute electrophysiologic means, as well as by long-term clinical follow-up ranging from 1 to 47 months. Sustained reciprocating tachycardia was rendered noninducible in 13 of 18 patients with WPW and in 5 of 6 with AVNRT. Long-term control of symptomatic tachycardia was achieved in 77% of patients with WPW and in 57% of patients with resistant AVNRT. Side effects were those associated with beta blockade. Two patients developed ventricular irritability associated with excessive QT prolongation.
Millar
R N
RN
Department of Medicine, Groote Schuur Hospital, Observatory, South Africa.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013015:Sotalol / Q000627:therapeutic use*; D013611:Tachycardia, Atrioventricular Nodal Reentry / Q000188:drug therapy* / Q000503:physiopathology; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy* / Q000503:physiopathology
D013015:Sotalol